^
    Back
    Association details:
    Biomarker:AR-V7 expression
    Cancer:Prostate Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

    Excerpt:
    ...Durable Progression Free Survival (PFS)`Number of Participants Experiencing Adverse Events`Objective Response Rate (ORR)`Overall Survival`Progression Free Survival (PFS)`Number of Participants With Change in AR-V7 Expression`PSA-PFS`Response Duration in Patients With Objective Response`Number of Participants With Change in AR-V7 Expression as Expressed by AR-V7 to Full Length AR Ratio Converting From AR-V7-positive to -Negative With Changes in AR-V7 Expression...
    Trial ID:
    STARVE-PC
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Prostate
    Title:

    Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial

    Published date:
    02/26/2021
    Excerpt:
    Nivolumab plus ipilimumab demonstrated only modest activity in patients with AR-V7-expressing prostate cancer...
    DOI:
    10.1002/pros.24110